Click me
Transcribed

Merck (MRK) Relative Performance

RELATIVE PERFORMANCE Change in Price Over Last Five Years 65.93% 95.55% 210% Merck S&P 500 S&P Pharmaceutical Index 5yr Relative Performance 250% 200% -Merck 150% S&P Pharmaceutical Index 100% S&P 500 50% Nov 08 Nov 09 Nov 10 Nov 11 Nov 12 -50% Merck and S&P 500 YTD Performance Merck S&P 500 30 25 20 15 10 Jan Mar May July Sept Nov Merck has underperformed the S&P 500 year to date by 8.51 percentage points. This is attributable to a continuous decline in Singulair sales, and Merck's inability to develop a new blockbuster drug. 52-week high 52-week low $50.16 $40.02 BIDNESS SOURCES: Company Data, SEC filings, Bloomberg Professional Services Etc. DISCLAIMER: Bidness Etc(TM) and related marks are owned by Bidness Etc. Any other trademarks appearing on this website are the property of their respective owners, and are not used to indicate the origin of goods or services offered or provided by Bidness Etc herein or to suggest approval for or affiliation with Bidness Etc. % Change

Merck (MRK) Relative Performance

shared by danialwilson on Apr 05
37 views
0 shares
0 comments
Merck (MRK) Relative performance: Over the last five years Merck has been underperforming the S&P 500 index and the S&P Pharmaceutical Index due to decline in sales after patent expires.

Tags

None.

Category

Health
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size